Thomas Powles

机构：Queen Mary University of London, Barts Health NHS Trust, National Institute for Health and Care Excellence, National Institute for Health and Care Research · ORCID：0000-0001-7760-4724

发表论文 684 篇 · 总被引 38934 次 · h-index 82

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 123)
• HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors (2025 · Future Oncology · 被引 9)
• Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer (2026 · New England Journal of Medicine · 被引 8)
• Antibody–drug conjugates in combination therapy: defining the next chapter (2025 · Annals of Oncology · 被引 5)
• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers (2025 · CA A Cancer Journal for Clinicians · 被引 2)
• Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (2026 · New England Journal of Medicine · 被引 1)